Upcoming events – Milestone's milestone and Transmedics' panel
Soon Milestone will report pivotal data with etripamil, an intranasal heart arrhythmia therapy, and an FDA adcom approaches for Transmedics' heart preservation…
Esperion shifts to show not tell
After spending years insisting that its cholesterol-lowering medicine has a place between statins and PCSK9 inhibitors, Esperion must now prove it.
A listless quarter for Medtronic
Medtronic has lined up a whole pipeline of new devices – and it will need them.
Biopharma’s big bet on cancer is laid bare
Drug developers have directed almost half of their dealmaking firepower at oncology projects over the past five years, with cardiovascular a distant second.
ACC preview: a veri important test for Merck and Bayer
Heart failure data must repay Bayer and Merck & Co for taking a chance on vericiguat, and a hit for Medtronic’s renal denervation system could erase the shame of its…
The cost to Astrazeneca of building Brilinta
Thales, the final Brilinta outcome trial in Astrazeneca’s huge Parthenon programme, has hit – but the UK group’s vast investment in its blood thinner has yet to pay off.
Bioresorbable scaffolds flounder as Reva heads to bankruptcy
With Reva, Amaranth and Abbott out of the game, the pool of dissolving scaffold makers is shrinking.
Upcoming events – Bayer and Merck look to vericiguat, and Akero bets on Nash
Bayer and Merck & Co need Vitality data to breathe life into vericiguat, while Akero awaits its first big test with the Nash project AKR-001.
Astra and Acasti throw the Amarin bulls more fodder
Amarin must hope that setbacks for Astrazeneca and Acasti show that in Vascepa it has the secret sauce.
